Dalvir Gill
Chief Executive Officer and Member of the Board of Directors, TransCelerate Biopharma
Meet Dalvir Gill
Dalvir Gill was appointed CEO of TransCelerate in January 2013 and has since pioneered a number of changes and improvements to the drug development process. As the CEO of TransCelerate and its subsidiary BioCelerate, Dalvir has led a number of initiatives that have helped to make the research and development ecosystem more efficient, safe and innovative. Through TransCelerate, he has made it a priority to not only engage with patients about clinical trials, but to also offer higher value to patients and other healthcare stakeholders through more effective use of trial information.